CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Lenz Therapeutics Inc - LENZ CFD

23.77
3.48%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023401 %
Charges from full value of position ($-4.45)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023401%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001179 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001179%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 22.97
Open 22.26
1-Year Change 602.21%
Day's Range 22.26 - 24.47
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2025 23.77 1.52 6.83% 22.25 24.50 22.23
Apr 16, 2025 22.97 0.60 2.68% 22.37 23.21 21.60
Apr 15, 2025 23.75 0.73 3.17% 23.02 24.15 22.31
Apr 14, 2025 23.19 1.60 7.41% 21.59 23.48 20.79
Apr 11, 2025 20.13 2.69 15.42% 17.44 20.26 17.44
Apr 10, 2025 18.48 -0.94 -4.84% 19.42 19.42 17.71
Apr 9, 2025 20.24 2.76 15.79% 17.48 20.40 16.26
Apr 8, 2025 18.20 -1.65 -8.31% 19.85 20.70 18.02
Apr 7, 2025 19.31 -0.64 -3.21% 19.95 21.48 18.72
Apr 4, 2025 21.04 -0.52 -2.41% 21.56 21.96 19.96
Apr 3, 2025 22.89 -1.06 -4.43% 23.95 24.77 22.78
Apr 2, 2025 25.42 0.25 0.99% 25.17 25.54 24.49
Apr 1, 2025 25.96 1.19 4.80% 24.77 26.71 24.77
Mar 31, 2025 25.65 1.09 4.44% 24.56 25.66 24.02
Mar 28, 2025 25.58 -0.94 -3.54% 26.52 26.88 25.22
Mar 27, 2025 26.47 0.71 2.76% 25.76 26.70 25.69
Mar 26, 2025 26.06 -0.44 -1.66% 26.50 26.50 25.07
Mar 25, 2025 26.38 0.99 3.90% 25.39 27.36 25.39
Mar 24, 2025 26.61 -0.02 -0.08% 26.63 27.45 26.27
Mar 21, 2025 26.43 0.77 3.00% 25.66 26.57 24.36

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Graphite Bio, Inc. Company profile

About Graphite Bio Inc

Graphite Bio, Inc. is clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. The Company's gene editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. The Company's pipeline includes multiple programs including its gene replacement program, GPH201 for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene prevent normal immune system function, and targeted gene insertion program, GPH301 for Gaucher disease, and multiple additional programs in both HSCs and other cell types.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Graphite Bio Inc revenues was not reported. Net loss increased 3% to $70.8M. Higher net loss reflects Research and development - Balancing val increase from $9M to $35.2M (expense), General and administrative - Balancing v increase from $4.3M to $17.3M (expense), Stock-based Compensation in SGA increase from $54K to $5.2M (expense).

Industry: Bio Therapeutic Drugs

611 Gateway Blvd, Suite 120
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

XRP/USD

2.08 Price
+0.000% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01040

Gold

3,327.76 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0169%
Short position overnight fee 0.0087%
Overnight fee time 21:00 (UTC)
Spread 0.30

ETH/USD

1,591.94 Price
-1.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

US100

18,303.00 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 720,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading